Trial Profile
A Phase II Trial of Panobinostat in Patients With Gastrointestinal Neuroendocrine Tumors.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Jun 2017 Status changed from completed to discontinued.
- 29 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 24 Feb 2014 Planned End Date changed from 1 Dec 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.